Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

BOULDER, Colo., Sept. 4, 2015 -Nivalis Therapeutics, Inc. (NASDAQ: NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis, today announced that Chief Executive Officer Jon Congleton will present a corporate overview at the Rodman and Renshaw 17thAnnual Global Investment Conference and the Baird 2015 Healthcare Conference.
Details of the two presentations are as follows:

Rodman and Renshaw 17thAnnual Global Investment Conference

Date: Wednesday, September 9th
Location: The St. Regis Hotel, New York
Presentation Time: 10:50 AM EDT

Baird 2015 Healthcare Conference

Date: Thursday, September 10th
Location: The New York Palace, New York
Presentation Time: 8:30 AM EDT
Individuals may access a live webcast of the conference presentations on the Nivalis website
at www.nivalis.comunder 'IR Calendar' in the 'News / Events' section. A replay of the webcast will be available on this site for 90 days following the live event.

About Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with cystic fibrosis. In addition to developing innovative solutions intended to extend and improve the lives of people with cystic fibrosis, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Investor Relations Contact
John Graziano
1-646-378-2942 jgraziano@troutgroup.com
Media Contact
Lindsay Rocco
1-862-596-1304
lrocco@elixirhealthpr.com

distributed by